Adepend launched for alcohol dependence

Adepend (naltrexone) is licensed for the maintenance of abstinence in alcohol dependence.

Naltrexone, a long-acting opioid antagonist, reduces the risk of abstinence relapse and alcohol cravings
Naltrexone, a long-acting opioid antagonist, reduces the risk of abstinence relapse and alcohol cravings


Naltrexone is a long-acting opioid antagonist that binds competitively to receptors in the central and peripheral nervous systems. Its exact mechanism of action in the treatment of alcohol dependence is unknown. The reinforcing effect of alcohol consumption is thought to be related to stimulation of the endogenous opioid system, and naltrexone may work by interacting with this system.1

To prevent serious withdrawal symptoms, prescribers must ensure patients are opioid-free before initiating therapy. Patients should be warned not to use opioids (eg, cough and cold remedies or anti-diarrhoeals) during treatment with naltrexone.1


The efficacy and safety of naltrexone in the treatment of alcohol dependence was assessed in a systematic review of 50 double-blind randomised controlled trials (n=7793) that compared naltrexone or nalmefene with placebo or active control. Naltrexone reduced the risk of heavy drinking by 17% compared with placebo (RR 0.83, 95% CI 0.76–0.90). In addition, drinking days were reduced by approximately 4% (mean difference –3.89%; 95% CI –5.75 to –2.04).2

In a meta-analysis of seven randomised controlled trials, naltrexone was superior to placebo in the maintenance of alcohol abstinence. Significantly fewer episodes of relapse were observed with naltrexone than placebo, and significantly more patients in the naltrexone group remained abstinent following 12 weeks of treatment compared with the control group.3

Adverse events related to naltrexone were mainly gastrointestinal and sedative effects. In the meta-analysis, there was no significant difference between naltrexone and placebo in the number of patients with at least one adverse event, or the number of patients who discontinued treatment owing to an adverse event.2,3


  1. Adepend Summary of Product Characteristics, December 2011.
  2. Rosner S et al. Cochrane Database Syst Rev 2010; 12: CD001867.
  3. Streeton C et al. Alcohol Alcohol 2001; 36: 544-52.

View Adepend drug record
Further information: AOP Orphan Pharmaceuticals

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases